The Federal Trade Commission issued a civil investigative demand to Johnson & Johnson in June regarding its contracting practices for the arthritis drug, the company said in a regulatory filing on July 29.
- NOTE: Pfizer sued J&J in 2017 for seeking to preserve a monopoly on the drug to ensure biosimilars would not become viable competitors
- NOTE: J&J May Have to Face Cancer-Warning Suit With Added Defendants
©2019 Bloomberg L.P. All rights reserved. Used with permission